Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA101 crossover study in chronic idiopathic cough and idiopathic pulmonary fibrosis-associated chronic cough
NL-OMON42283Phase 2Active, not recruiting
- Sponsor
- Patara Pharma
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of RVT-1601 in chronic idiopathic cough (CIC) and idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Patara Pharma. Primary endpoints: Change from baseline in 24-hour objective cough count, Change from baseline in average daytime cough count and 5 more. Started Feb 2015; status: active, not recruiting.
02
Drugs
RVT-1601
03
Conditions
chronic idiopathic cough (CIC)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON42283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42283.